• Home
  •  / Loxo Oncology
ProfileJobs (64)

Loxo Oncology

Suggest Edit
Healthcarebiotechoncologypharma

Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. The Company bases its approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. Loxo Oncology is developing a pipeline of highly selective drugs that inhibit oncogenic drivers in cancer.

TypeSubsidiary
Parent CompanyEli Lilly
HQStamford, CT, US
Founded2013
Websiteloxooncology.com
Cybersecurity ratingBMore
Loxo Oncology was founded in 2013 and is headquartered in Stamford, CT, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Loxo Oncology

Jacob S. van Naarden

Jacob S. van Naarden

Chief Executive Officer
Nisha Nanda

Nisha Nanda

Chief Development Officer
David Hyman

David Hyman

Chief Medical Officer
Steve Andrews

Steve Andrews

Senior Vice President, Small Molecule Discovery
Barb Brandhuber

Barb Brandhuber

Vice President, Small Molecule Biology
Kyla Driscoll

Kyla Driscoll

Executive Director, Biologics Discovery
Show more

Loxo Oncology Office Locations

Loxo Oncology has offices in Stamford, Boulder, New York, South San Francisco and in 2 other locations
Stamford, CT, US (HQ)
281 Tresser Blvd, 14th Floor
Boulder, CO, US
3122 Sterling Cir #200
New York, NY, US
450 E 29th St
South San Francisco, CA, US
701 Gateway Blvd #420
Alcobendas, ES
Av. de la Industria, 30
Show all (6)

Loxo Oncology Financials and Metrics

Summary Metrics

Founding Date

2013

Total Funding

$57 m

Investors

New Enterprise Associates, OrbiMed Advisors, Aisling Capital, OrbiMed
In total, Loxo Oncology had raised $57 m. Loxo Oncology is a subsidiary of Eli Lilly

Loxo Oncology Revenue

Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

General and administrative expense

6.2m10.5m14.9m33.7m

R&D expense

6.9m14.0m58.3m140.0m

Operating expense total

13.1m24.5m73.2m173.7m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

38.4m42.6m42.5m

General and administrative expense

1.3m1.7m2.4m2.4m2.6m3.4m3.8m3.7m4.8m6.5m9.7m12.2m15.7m15.9m

R&D expense

855.0k2.6m1.9m2.8m3.4m8.4m12.3m14.2m20.2m24.4m64.8m32.0m41.6m56.9m

Operating expense total

2.2m4.3m4.3m5.2m5.9m11.8m16.1m17.9m24.9m30.9m74.4m44.2m57.3m72.8m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

43.9m68.2m30.4m142.0m

Accounts Receivable

1.1b

Prepaid Expenses

5.6m

Current Assets

107.8m156.6m141.8m781.8m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

51.3m118.6m37.3m36.6m34.4m47.5m52.9m51.9m48.5m260.3m80.4m103.8m147.7m136.1m

Prepaid Expenses

651.0k1.4m555.0k410.0k2.1m2.4m2.8m4.1m4.1m3.8m4.9m5.9m5.7m6.3m

Current Assets

52.0m120.0m99.2m103.2m96.4m147.3m174.5m159.6m244.4m471.4m376.6m720.6m676.7m628.3m

PP&E

7.0k13.0k31.0k78.0k74.0k303.0k291.0k269.0k328.0k364.0k566.0k1.6m3.3m4.3m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(20.7m)(35.9m)(72.4m)(148.9m)

Depreciation and Amortization

1.0k17.0k77.0k205.0k

Accounts Payable

18.0k30.0k792.0k2.9m

Cash From Operating Activities

(2.8m)(30.2m)(51.3m)107.8m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(6.8m)(13.5m)(6.2m)(14.2m)(23.0m)(11.6m)(27.5m)(45.2m)(24.5m)(54.9m)(128.2m)(3.6m)(15.3m)(42.3m)

Depreciation and Amortization

1.0k60.0k157.0k296.0k121.0k274.0k452.0k97.0k170.0k222.0k(165.0k)(573.0k)(1.1m)

Accounts Payable

355.0k(14.0k)46.0k176.0k492.0k489.0k408.0k752.0k192.0k1.1m768.0k1.8m793.0k(2.0m)

Cash From Operating Activities

(6.4m)(12.1m)(5.3m)(11.2m)(19.5m)(9.5m)(21.4m)(36.7m)(26.7m)(50.5m)(113.4m)109.8m74.8m13.4m
show all
USDQ2, 2014

Financial Leverage

-3.2 x
Show all financial metrics

Loxo Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

Learn more about our premium products
SecurityScorecard logo

Loxo Oncology Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Loxo Oncology Online and Social Media Presence

Loxo Oncology's Trends

Embed Graph

Loxo Oncology News and Updates

March 05, 2021

Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet

INDIANAPOLIS, March 5, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as LOXO-305) global Phase 1/2 BRUIN clinical trial...
December 05, 2020

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting

INDIANAPOLIS, Dec. 5, 2020 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced clinical data from the LOXO-305 global Phase 1/2 BRUIN clinical trial in mantle cell lymphoma (MCL) and other non-Hodgkin lymphomas....
February 15, 2019

Lilly Completes Acquisition of Loxo Oncology

INDIANAPOLIS, Feb. 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (NASDAQ:LOXO). The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines through the addition of ...
February 06, 2019

Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology

INDIANAPOLIS, Feb. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2018. $ in millions, except per share data Fourth Quarter % Full Year % 2018 2017 Change 2018 2017 Change Revenue $ 6,438.6 $ 6,160.7 5% $ ...
February 01, 2019

Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction

INDIANAPOLIS and STAMFORD, CT, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the…
January 08, 2019

WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests of LOXO Shareholders

NEW YORK, Jan. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc. ("LOXO" or the "Company") (NASDAQ: LOXO) in connection with the proposed acquisition of the Company by Eli...
Show more

 Loxo Oncology Frequently Asked Questions

  • When was Loxo Oncology founded?

    Loxo Oncology was founded in 2013.

  • Who are Loxo Oncology key executives?

    Loxo Oncology's key executives are Jacob S. van Naarden, Nisha Nanda and David Hyman.

  • How many employees does Loxo Oncology have?

    Loxo Oncology has 334 employees.

  • Who are Loxo Oncology competitors?

    Competitors of Loxo Oncology include Repare Therapeutics, Symphogen and Chugai Pharmaceutical.

  • Where is Loxo Oncology headquarters?

    Loxo Oncology headquarters is located at 281 Tresser Blvd, 14th Floor, Stamford.

  • Where are Loxo Oncology offices?

    Loxo Oncology has offices in Stamford, Boulder, New York, South San Francisco and in 2 other locations.

  • How many offices does Loxo Oncology have?

    Loxo Oncology has 6 offices.